Trial
NCT04003610
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Metastatic Urothelial Carcinoma
Intervention
Pemigatinib
Why stopped
The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-04